[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-transplant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-transplant":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,55,92,116,144,169,194,222],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100645075","comparison-of-the-effects-of-general-anesthesia-and-combined-spinal-epidural-anesthesia-on-ferroptosis-humanin-and-mots-c-levels-in-renal-transplantation-100645075",false,"NCT07678073","COMPARISON OF THE EFFECTS OF GENERAL ANESTHESIA AND COMBINED SPINAL-EPIDURAL ANESTHESIA ON FERROPTOSIS, HUMANIN, AND MOTS-C LEVELS IN RENAL TRANSPLANTATION","COMPARISON OF THE EFFECTS OF GENERAL ANESTHESIA AND COMBINED SPINAL-EPIDURAL ANESTHESIA ON FERROPTOSIS, HUMANIN, AND MOTS-C LEVELS IN RENAL TRANSPLANTATION: A PROSPECTIVE CONTROLLED STUDY","Inclusion Criteria:\n\n* Patients aged 18-70 years with American Society of Anesthesiologists (ASA) physical status I-III.\n* Patients scheduled for elective living-donor allogeneic kidney transplantation.\n* Patients receiving sevoflurane-based general anesthesia as the anesthetic technique.\n* Patients receiving combined spinal-epidural anesthesia as the anesthetic technique.\n\nExclusion Criteria:\n\n* Patients younger than 18 years or older than 70 years.\n* Patients undergoing deceased-donor kidney transplantation.\n* Patients receiving total intravenous anesthesia (TIVA).\n* Patients who decline to participate in the study or are unable to provide informed consent.\n* Patients with American Society of Anesthesiologists (ASA) physical status IV or V.\n* Patients with a history of previous organ transplantation.\n* Patients with known or suspected mitochondrial disorders.\n* Patients with a history of chronic corticosteroid use.\n* Patients requiring red blood cell transfusion intraoperatively or within the first 24 postoperative hours.\n* Patients with a primary warm ischemia time \\>5 minutes, secondary warm ischemia time \\>30 minutes, or cold ischemia time \\>60 minutes.","ALL","18 Years","70 Years",{"count":20,"type":21},68,"ESTIMATED","INTERVENTIONAL",[24],"NA","Renal transplantation is the most effective renal replacement therapy for patients with end-stage renal disease. Ischemia-reperfusion injury may adversely affect graft function and long-term outcomes. Ferroptosis has recently emerged as a potential mechanism involved in ischemia-reperfusion injury, while the mitochondrial-derived peptides humanin and MOTS-c are thought to exert protective effects against oxidative stress. However, the effects of different anesthetic techniques on these biomarkers in kidney transplant recipients have not been investigated.\n\nThis prospective controlled study aims to compare the effects of sevoflurane general anesthesia (SGA) and combined spinal-epidural anesthesia (CSEA) on serum ferroptosis markers, humanin, and MOTS-c levels in adult kidney transplant recipients. Blood samples will be obtained perioperatively for biomarker analysis.\n\nThe primary objective of the study is to evaluate the effects of the anesthetic technique on serum ferroptosis markers, humanin, and MOTS-c levels. Secondary objectives include evaluating early graft function and postoperative outcomes by assessing the incidence of delayed graft function, postoperative serum creatinine levels, requirement for dialysis, urine output, length of hospital stay, and the association of these outcomes with perioperative biomarker levels.",[27,28,29,30,31],"Kidney Disease, End-Stage","Kidney Transplant","Kidney","Kidney Disease","Renal Transplant",[33,34,35,36,37,38,39,40,41],"GENERAL ANESTHESIA","REGIONAL ANESTHESIA","KIDNEY TRANSPLANTATION","CELLULAR STRESS RESPONSE","CELLULAR STRESS","ANESTHESIA","HUMANIN","MOTS-c","FERROPTOSIS","RECRUITING","2026-06-24",{"date":45,"type":46},"2026-07-01","ACTUAL",{"date":48,"type":46},"2026-03-01",{"date":50,"type":21},"2026-10-15",{"name":52,"class":53},"University of Gaziantep","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":64,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":54},"100642745","microvasculature-ultrasound-super-resolution-in-transplant-delayed-graft-function-100642745","NCT07645599","Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function","MUST-D","Inclusion Criteria:\n\nFor stage 1 of the study:\n\n1. We will enroll patients ≥18 years of age\n2. Patients who received a kidney transplant 2a. Patients requiring dialysis in the first 14 days after transplant 2b. Patients with working allografts not requiring dialysis (control group)\n\nFor stage 2 of the study\n\n1. We will enroll patients at least 18 years of age or older\n2. Patients who received a kidney transplant 2a. Patients who received kidney transplants from low KDPI kidneys (KDPI \\\u003C 35) 2b. Patients who received kidney transplants from high KDPI kidneys (KDPI \\> 75)\n\nExclusion Criteria:\n\n1. BMI \\> 40\n2. Inability to provide informed consent\n3. Pregnant woman\n4. Breastfeeding women\n5. Hypersensitivity to perfluten lipid microsphere and components including polyethylene glycol (PEG)\n6. Unstable cardiopulmonary condition (acute myocardial infarction, acute coronary artery symptoms, worsening or unstable congestive heart failure, serious ventricular arrhythmias).\n7. Known history of cardiac shunts\n8. Patients who have known sickle cell disease or trait",{"count":63,"type":21},40,"3 Years","OBSERVATIONAL","This pilot study is testing a new ultrasound imaging method called Super-Resolution Ultrasound (SRU) to look at blood flow and tiny blood vessels in transplanted kidneys in very detailed images after kidney transplant surgery. The goal is to see whether changes in the kidney's small blood vessels can help predict how well the transplanted kidney will work early after transplant, including whether delayed graft function may occur.\n\nInvestigators hope this technique can become a safe, noninvasive way to evaluate transplanted kidneys without needing as many invasive biopsies. It may also help doctors better assess donor kidneys at higher-risk of suboptimal functioning.",[68,31,69,70],"End Stage Chronic Renal Failure","Microvascular Changes","Microvascular Circulation",[72,73,74,75,76,77,78,79,80,81],"renal allograft","kidney allograft","kidney transplant","super-resolution ultrasound","lipid microspheres","renal microvasculature","kidney microvasculature","delayed graft function","Kidney Donor Profile Index","deceased donor kidney transplant","NOT_YET_RECRUITING","2026-06-08",{"date":85,"type":46},"2026-06-12",{"date":87,"type":21},"2026-06-01",{"date":89,"type":21},"2028-06-30",{"name":91,"class":53},"Roderick Tan",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":54},"100538232","evaluation-of-thiosulfate-enhanced-organ-preservation-solution-in-kidney-transplantation-100538232","NCT06288152","Evaluation of Thiosulfate Enhanced Organ Preservation Solution in Kidney Transplantation","Inclusion Criteria:\n\n* 18 years of age and over\n* End-Stage Renal Disease\n* Receiving a kidney transplant from a deceased donor (NDD or DCD)\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Inability to provide informed consent\n* Living donor kidney recipients\n* Pregnant individuals\n* Known allergy to study medication or its components (non-medicinal ingredients)\n* Multiorgan transplant patients such as simultaneous kidney pancreas or liver kidney transplants\n* Currently enrolled in another interventional transplant clinical trial, or another clinical trial that in the opinion of the QI and PI would greatly impact the results of this study.",{"count":99,"type":21},120,[24],"End-stage renal disease (ESRD) is a significant clinical problem for which dialysis or transplantation is required. The current need for kidneys for transplantation vastly exceeds the supply available from live donors, necessitating the use of kidneys from deceased donors. However, kidneys from deceased donors are associated with reduced viability, as lack of blood supply upon cardiac death increases tissue damage. In addition, the standard protocol for cold preservation of donor kidneys between procurement and transplantation increases the risk of delayed donor kidney function by 23% for every 6-hours of storage. Moreover, compared to other organs, the kidney is particularly prone to transplantation-induced injury due to its high metabolic activities and oxygen consumption. Hence, any minor disturbances in blood supply can easily lead to kidney injury. Therefore, it is not surprising that deceased donor kidneys have a low tolerance for damage associated with lack of blood supply. The focus of the investigators research has been to pioneer the development and supplementation of existing kidney preservation solutions with novel hydrogen sulfide (H2S) donor molecules to improve kidney viability for clinical transplantation. Specifically, the investigators demonstrated that supplementation of standard kidney preservation solutions with non-clinically viable H2S donor molecules significantly increased donor kidney protection and prolonged transplant recipient survival in murine and porcine models of kidney transplantation. Having shown the same salutary effect using sodium thiosulfate (STS; a clinically viable H2S donor drug) in rat kidney transplantation, the investigators aim to repeat this work using STS in porcine and clinical kidney transplantation.\n\nThis single-blind study will enroll participants receiving a kidney transplant. Through randomization, half of the participants will receive STS through administration into the pump the kidney is placed on after procurement from the donor and before transplant to the recipient. Participants will be followed for 1-year post transplant where blood and urine will be collected to determine graft function.",[31,28],[104,105,106,29],"Thiosulfate","Transplant","Renal","2026-04-07",{"date":109,"type":46},"2026-04-13",{"date":111,"type":46},"2025-05-03",{"date":113,"type":21},"2027-03-01",{"name":115,"class":53},"Alp Sener",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100619765","predictive-accuracy-of-machine-perfusion-for-kidney-transplant-outcomes-in-germany-100619765","NCT07348874","Predictive Accuracy of Machine Perfusion for Kidney Transplant Outcomes in Germany","Predictive Accuracy of Machine Perfusion Parameters for Kidney Allograft Outcome - A National Analysis Following the Commencement of Hypothermic Machine Preservation of Extended Criteria Donor (ECD) Kidneys in Germany","PRE-MAP-Kidney","Inclusion Criteria:\n\n1. Signed informed consent\n2. Patients 18 years or older\n3. Listed for kidney transplantation (KT)\n4. Receiving ECD\\* donation after brain death kidney allografts following national organ procurement\n5. Kidney allograft being transported at continuous HMP\n6. Transplantation of recipient at a national transplant center\n\n   * Extended Criteria Donation:\n\n1\\. Donor age ≥ 60 years 2. Donor age 50 - 59 plus 2 additional attributes: I. Arterial hypertension in medical history II. Last serum creatinine \\>1.5mg\u002FdL (133mmol\u002FL) III. Cerebrovascular cause of death\n\nExclusion Criteria:\n\n1. Recipients of living donor KT\n2. Combined transplantations (liver-kidney, kidney-pancreas, etc.)\n3. Participation in another intervention-trial with interference of intervention and\u002For outcome of this study\n4. Unwilling or unable to follow the procedures outlined in the protocol\n5. Mentally or legally incapacitated\n6. Inability to understand the procedures due to language barriers",{"count":125,"type":21},300,"Kidney transplantation remains the only definitive treatment for end-stage renal disease, yet the increasing use of extended criteria donor (ECD) kidneys heightens the risk of ischemia-reperfusion injury, particularly under static cold storage (SCS). Continuous hypothermic machine perfusion (HMP) has been introduced to improve preservation quality, but robust clinical evidence regarding its predictive value for post-transplant outcomes in ECD kidneys after donation after brain death (DBD) is limited.\n\nThe PRE-MAP Kidney Study is a prospective, non-interventional, multicenter observational study conducted across all German transplant centers. The study systematically collects technical machine perfusion parameters (flow, resistance, perfusion duration) and correlates these with clinical outcomes following kidney transplantation.\n\nThe primary endpoint is 12-month kidney function (eGFR). Secondary endpoints include surgical complications, length of stay, and transplant-specific events (acute rejection, primary non-function, delayed graft function).\n\nThis national cohort aims to determine the prognostic significance of HMP parameters in marginal donor kidneys and to generate evidence supporting future recommendations for organ preservation and allocation practices.",[28,31,128],"Organ Preservation",[130,131,132,133,128,134],"Machine Perfusion","Hypothermic Machine Perfusion","Upfront Machine Perfusion","Continuous Machine Perfusion","Marginal Allograft","2026-01-09",{"date":137,"type":46},"2026-01-16",{"date":139,"type":21},"2026-01-19",{"date":141,"type":21},"2028-02-01",{"name":143,"class":53},"University Hospital Heidelberg",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":54},"100608100","phase-2-safety-and-effectiveness-of-a-remdesivir-treatment-to-prevent-severe-covid-19-in-kidney-transplant-patients-100608100","NCT07197164","Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients","Safety and Efficacy of 10-day Course of Remdesivir to Prevent Severe COVID-19 in Asymptomatic or Paucisymptomatic SARS-COV-2-positive Kidney Transplant Recipients: a Single-arm Proof-of-concept Interventional Trial","COVIDKIDNEY","Inclusion Criteria:\n\n1. At least 18 years-old\n2. Patients with end-stage kidney disease that are included on the local kidney transplant waiting list who get an offer of a compatible organ and, subsequently, have a transplant procedure scheduled in the next 24 (+\u002F-) 12 hours, or patients with end-stage kidney disease that are planned to receive a non-cadaveric donor kidney transplant on the following 5 days.\n3. Have a positive SARS-CoV-2 nasopharyngeal PCR or RAT within 5 days prior to transplant surgery.\n4. Have previously received at least three SARS-CoV-2 vaccine doses, with a minimum time elapsed of 3 months since the last dose received.\n5. Are asymptomatic or have mild acute COVID-19 symptoms during the previous 5 days (headache, sore throat, cough, chest pain, nausea, diarrhea, fatigue, loss of smell or taste, myalgia) excluding fever in the previous 48 hours (\\>38ºC) or shortness of breath.\n6. Post-menopausal or fertile females (females who are not surgically sterile or postmenopausal defined as amenorrhea for \\>12 months) that agree to avoid pregnancy during the study. If sexually active fe-male; using highly effective contraceptive methods (hormonal contraception, intra-uterine device (IUD), or anatomical sterility in self or partner\\*) while on study treatment. All female volunteers must be willing to undergo urine pregnancy tests at time of enrollment.\n7. Having understood the information provided and capable of giving consent to participate in this trial by signing the Informed Consent document.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women, at time of enrollment\n2. Patients requiring supplementary oxygen at baseline or diagnosed with severe COPD or pulmonary fibrosis.\n3. Patients having any of the following at the screening period: i) O2 saturation below 94% on room air; ii) respiratory frequency of \\> 30bpm; or iii) Xray showing new-onset pulmonary infiltrates suggesting COVID-19 pneumonia.\n4. Patients having fever (\\>38ºC) in the last 48 hours or shortness of breath in the previous 5 days.\n5. Previous history of hypersensitivity, documented allergy or contraindications to receive remdesivir.\n6. ABO incompatible kidney transplant\n7. Desensitization therapy indicated as induction therapy for high immunological risk transplant with Donor Specific HLA Antibodies (DSA)\n8. Participants who receive different types of induction immunosuppression other than the standard induction protocols with lymphocyte- depleting agents (thymoglobulin or basiliximab).\n9. Active liver disease with AST or ALT \\>3 ULN, Total bilirubin ≥2 × ULN (for Gilbert's syndrome, direct bilirubin \\>ULN is exclusionary) within the past 3 months, or liver function impairment with Class B or C per Child Pugh classification.\n10. Suspected or confirmed concurrent active respiratory infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.\n11. Any comorbidity requiring hospitalization and\u002For surgery within 7 days prior to study entry, or that is considered life threatening within 30 days prior to study entry, as determined by the investigator.\n12. Prior participation in this trial.\n13. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.",{"count":153,"type":21},15,[155],"PHASE2","Since the start of the COVID-19 pandemic, the approach to solid organ transplantation has evolved. Transplants using organs (excluding lungs) from COVID-19-positive donors have shown short-term safety, but there is limited data on recipients who are SARS-CoV-2 positive. Currently, kidney transplants in such recipients are delayed until symptoms resolve and a negative PCR is preferred, despite the risks of prolonged dialysis and increased cold ischemia time.\n\nRecent data from the Omicron era suggest that early antiviral treatment may reduce complications. Immunosuppressive therapy might even help mitigate severe inflammatory responses. The proposed study aims to show that kidney transplantation can be safely performed in asymptomatic or mildly symptomatic COVID-19-positive recipients who begin antiviral treatment (remdesivir) within 24 hours before transplant and continue for 10 days. This could reduce waiting times and improve outcomes.\n\nRemdesivir is an antiviral safe for use in patients with low kidney function, including those on dialysis or post-transplant, with minimal side effects. The hypothesis is that this treatment strategy can prevent progression to severe COVID-19 and allow safe transplantation",[158,31,159],"COVID - 19","SARS CoV 2 Infection","2025-09-26",{"date":162,"type":46},"2025-09-29",{"date":164,"type":46},"2025-09-01",{"date":166,"type":21},"2027-02-28",{"name":168,"class":53},"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":54},"100606864","frailty-among-renal-transplant-recipients-and-relation-to-chronic-allograft-dysfunction-100606864","NCT07181096","Frailty Among Renal Transplant Recipients and Relation to Chronic Allograft Dysfunction","Study of Frailty Among Renal Transplant Recipients, Its Relation to Chronic Renal Allograft Dysfunction","Inclusion Criteria:\n\n* Renal transplanted patients with GFR more than 30\n\nExclusion Criteria:\n\n* Mentally or physically unfit patients.\n* Amputation of lower limb.\n* Active neoplasia, chronic liver disease, previous immunological disease.\n* Psychiatric disorders.\n* Pregnancy.",{"count":177,"type":21},80,[24],"The aim of the study is to assess prevalence of frailty among renal transplant recipients in Alexandria University Hospitals and to study the relation between frailty and chronic allograft dysfunction.",[181,31],"Frailty",[181,183,184],"renal transplant recipient","chronic allograft dysfunction","2025-09-12",{"date":187,"type":46},"2025-09-18",{"date":189,"type":46},"2025-07-15",{"date":191,"type":21},"2026-01-15",{"name":193,"class":53},"Alexandria University",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":206,"conditions":207,"keywords":210,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":54},"100597995","phase-4-negative-pressure-wound-therapy-in-renal-transplant-100597995","NCT07065734","NEgative prEssure Wound Therapy in Renal Transplant","NEgative prEssure Wound Therapy in Renal Transplant - NEWER Trial","NEWER","Inclusion Criteria:\n\n* All patients submitted to kidney transplant\n\nExclusion Criteria:\n\n* Pediatric patients, those requiring surgical reinterventions within the first 90 days postoperative, patients allergic to NPWT components, orthotopic transplant",{"count":203,"type":21},150,[205],"PHASE4","This is a prospective study involving patients undergoing open renal transplant. Renal transplant recipients were randomly divided into two groups: the NPWT group, which received NPWT, and the Standard group, which received standard wound dressings.",[208,31,209],"Transplant Complication","Wound Complication",[211,212,213],"transplant complication","renal transplant","wound complication","2025-07-10",{"date":189,"type":46},{"date":217,"type":46},"2023-01-01",{"date":219,"type":21},"2026-06-30",{"name":221,"class":53},"Centro Hospitalar De São João, E.P.E.",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":231,"conditions":232,"keywords":238,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":54},"100518030","expanding-the-scope-of-post-transplant-hla-specific-antibody-detection-and-monitoring-in-renal-transplant-recipients-100518030","NCT06025240","Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients","HLA-AB","Inclusion Criteria:\n\n1. cf-DNA arm:\n\n   * Adult patients transplanted within 6-12 months (retrospective recruitment)\n   * Patients admitted for renal transplant or within the first 6 months following transplant (prospective recruitment)\n   * Patients must have capacity to provide informed consent\n   * Patients must have received a high-risk transplant defined as level 4 mismatch, cRF \\>20, second or subsequent transplant, ABO or HLA incompatible\n2. Older Age Immunological Events:\n\n   \\- Any adult patient with capacity undergoing, or within 72 hours of, a renal transplant\n3. Predictive models:\n\n   * Any adult patient with capacity undergoing, or within 72 hours of, a renal transplant\n   * Unsensitized pre-transplant\n\nExclusion Criteria:\n\n1. cf-DNA arm:\n\n   * Transplanted for longer than 12 months;\n   * Low risk transplants;\n   * Patients lacking capacity;\n2. Older Age Immunological Events:\n\n   * Patients lacking capacity\n   * Patients transplanted longer than 2 weeks\n3. Predictive models:\n\n   * Sensitised patients\n   * Patients lacking capacity\n   * Patients transplanted longer than 2 weeks",{"count":230,"type":21},282,"The purpose of this study is to assess a new test to detect antibodies which may form following kidney transplant. These antibodies can be difficult to detect as they do not cause any symptoms but can lead to kidney damage. A new blood test will be performed alongside existing antibody tests to see how well the test functions in comparison and to see how well it is able to distinguish between inflammation caused by antibodies and other sorts of inflammation such as a urinary tract infection. The investigators also want to determine whether it is predictable whom will develop antibodies after a transplant and use these results to change the current way patients are monitored for antibodies after receiving a transplant. In addition to this, the investigators want to establish if patients over 60 years of age are relatively protected against immunological events such as rejection compared to patients who are under 60 years of age. The results could potentially lead to using a different immunosuppression regime based on which population age group patients belong to and lowering the risks associated with these drugs.",[28,233,234,181,235,236,237,31],"Renal Transplant Failure","Kidney Transplant Rejection","Kidney Transplant; Complications","Transplant Dysfunction","Diagnosis",[74,239,240,241,242,243,244,245,246],"novel biomarkers","post-transplant antibodies","HLA-specific antibodies","donor specific antibodies","transplant in older age","machine learning","predictive models","rejection","2024-08-28",{"date":249,"type":46},"2024-08-30",{"date":251,"type":46},"2023-10-13",{"date":253,"type":21},"2026-10-13",{"name":255,"class":256},"Liverpool University Hospitals NHS Foundation Trust","OTHER_GOV"]